Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.56 |
| ▸ | LPL | P06858 | 12/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.52 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069400 | 0.95 | LIPG (0.61) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21693475 | 0.86 | CA1 (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16797009 | 0.85 | CA1 (0.53) | CA1CA2CA9CA12CA3 | |
| SCHEMBL23758975 | 0.83 | CA1 (0.54) | CA1CA2CA9CA12CA3 | |
| SCHEMBL364006 | 0.83 | CA1 (0.71) | CA1CA2CA9CA12CA3 | |
| SCHEMBL29767445 | 0.82 | CA1 (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL20843085 | 0.81 | LIPG (0.57) | CA1CA2CA9CA12CA3 | |
| SCHEMBL228212 | 0.81 | LPL (0.71) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15574746 | 0.81 | DGAT1 (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL557918 | 0.80 | CA1 (0.51) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-119591599-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119591600-A | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and use thereof | 上海瑛派药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| EP-1781664-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | Methylgene, Inc. (CA) | 2007-05-09 | — | — | EP | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
| EP-1482924-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006010264-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2006-02-02 | — | — | WO | disclosed |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | disclosed |
| EP-1482924-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2004-12-08 | — | — | EP | disclosed |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | BAYLY CHRISTOPHER I (CA) | 2003-12-18 | — | — | US | disclosed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | CA1 4270/4885CA2 4145/4885CA9 3707/4885 |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | CA1 4568/4885CA2 4474/4885CA9 4180/4885 |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | CTSE, CTSB, CTSS | CA1 1360/4885CA2 1734/4885CA9 3352/4885 |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | CA1 4780/4885CA2 3271/4885CA9 2955/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | CA1 881/4885CA2 1128/4885CA9 2006/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | CA1 4780/4885CA2 3271/4885CA9 2955/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | CA1 4831/4885CA2 4610/4885CA9 4732/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | CA1 4576/4885CA2 4486/4885CA9 4184/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | CA1 3508/4885CA2 2899/4885CA9 915/4885 |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | CA1 1299/4885CA2 1519/4885CA9 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.